Literature DB >> 1764370

Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.

C M Barton1, S L Staddon, C M Hughes, P A Hall, C O'Sullivan, G Klöppel, B Theis, R C Russell, J Neoptolemos, R C Williamson.   

Abstract

The tumour suppressor gene p53 has been found to be mutated or inactivated at high frequency in several common human tumours. We have examined a series of exocrine pancreatic carcinomas for over-expression of mutant forms of p53 by immunohistochemistry with a panel of specific antibodies. We found immunodetectable p53 in 13 of 22 (60%) frozen pancreatic cancers and seven of 13 pancreatic cell lines. One of the antibodies, CM1, recognises p53 in formalin-fixed, paraffin-embedded archival material and using this reagent we found immunodetectable p53 in 28 of 124 (23%) pancreatic cancers. We have successfully demonstrated the presence of point mutations by direct sequencing of genomic DNA extracted from archival tissue showing CM1 immunoreactivity. We conclude that p53 activation is an important event in human pancreatic tumorigenesis and that the CM1 antibody can detect a proportion of cases of overexpression of mutant p53 in archival pathological material.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1764370      PMCID: PMC1977874          DOI: 10.1038/bjc.1991.467

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

Review 1.  Growth factors and oncogenes in pancreatic cancer.

Authors:  N R Lemoine; P A Hall
Journal:  Baillieres Clin Gastroenterol       Date:  1990-12

2.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.

Authors:  B Bressac; M Kew; J Wands; M Ozturk
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

3.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.

Authors:  S Srivastava; Z Q Zou; K Pirollo; W Blattner; E H Chang
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

4.  p53 mutations in colorectal cancer.

Authors:  N R Rodrigues; A Rowan; M E Smith; I B Kerr; W F Bodmer; J V Gannon; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

6.  Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.

Authors:  P A Wright; N R Lemoine; P E Goretzki; F S Wyllie; J Bond; C Hughes; H D Röher; E D Williams; D Wynford-Thomas
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

7.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; J Lukás; A Rejthar; J Kovarík; C A Midgley; J V Gannon; D P Lane
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

8.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

Review 9.  Mutational activation of the c-K-ras gene in human pancreatic carcinoma.

Authors:  D Shibata; G Capella; M Perucho
Journal:  Baillieres Clin Gastroenterol       Date:  1990-03

10.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

View more
  114 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 2.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

3.  Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; A Aboukameel; Zhiwei Wang; Sanjeev Banerjee; Syed F Zafar; Anton-Scott Goustin; K Almhanna; Dajun Yang; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Curr Cancer Drug Targets       Date:  2010-05       Impact factor: 3.428

4.  Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines.

Authors:  R A Perugini; T P McDade; F J Vittimberga; A J Duffy; M P Callery
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

5.  p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium.

Authors:  M D Jeffers; J Richmond; M Farquharson; A M McNicol
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

6.  Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype.

Authors:  Philip J Mitchell; Elena Perez-Nadales; Denise S Malcolm; Alison C Lloyd
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  Pancreatoblastoma in an adult: its separation from acinar cell carcinoma.

Authors:  A Hoorens; F Gebhard; K Kraft; N R Lemoine; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Expression of p53 protein in pancreatic adenocarcinoma. Relationship to cigaret smoking.

Authors:  E U Lee; M L Cibull; E O'Daniel-Pierce; W E Strodel; C D Jennings
Journal:  Int J Pancreatol       Date:  1995-06

9.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

10.  A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

Authors:  Paolo Monti; Federica Marchesi; Michele Reni; Alessia Mercalli; Valeria Sordi; Alessandro Zerbi; Giampaolo Balzano; Valerio Di Carlo; Paola Allavena; Lorenzo Piemonti
Journal:  Virchows Arch       Date:  2004-07-17       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.